Cargando…

Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis

Psoriasis is a chronic inflammatory skin disease affecting 2%–3% of the population. The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. This investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Duca, Ester, Farnetani, Francesca, De Carvalho, Nathalie, Bottoni, Ugo, Pellacani, Giovanni, Nisticò, Steven P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806803/
https://www.ncbi.nlm.nih.gov/pubmed/29048238
http://dx.doi.org/10.1177/0394632017736674
_version_ 1783299177669722112
author Del Duca, Ester
Farnetani, Francesca
De Carvalho, Nathalie
Bottoni, Ugo
Pellacani, Giovanni
Nisticò, Steven P
author_facet Del Duca, Ester
Farnetani, Francesca
De Carvalho, Nathalie
Bottoni, Ugo
Pellacani, Giovanni
Nisticò, Steven P
author_sort Del Duca, Ester
collection PubMed
description Psoriasis is a chronic inflammatory skin disease affecting 2%–3% of the population. The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. This investigator-initiated trial (IIT) evaluated the efficacy and the safety of a vitamin B(12)-containing ointment in comparison with glycerol-petrolatum-based emollient cream used twice a day to treat mild-to-moderate plaque psoriasis for a period over 12 weeks followed by a wash-out observation period of 4 weeks. This study was conducted as a randomized, controlled, single-blind, intra-patient left- to right-side trial comparing the efficacy and safety of vitamin B(12)-containing ointment (M-treatment) with a glycerol-petrolatum-based emollient cream (C-treatment). The Psoriasis Area Severity Index (PASI) was determined at baseline (T0), at time points T2 (14 days), T4 (4 weeks), T8 (8 weeks), T12 (12 weeks) and 4 weeks after the end of the wash-out period (F1). In total, 24 patients with plaque psoriasis were randomized to receive left- or right-side treatment with B(12) ointment. From time point T2 to time point F1, there was a statistically significant difference in PASI reduction between M-treatment side and C-treatment side. At time point T 12, the difference between the mean reductions from baseline PASI scores by 5.92 ± 2.49 (87, 6%) in the M-treatment side versus 1.08 ± 1.02 (23, 1%) C-treatment side was statistically highly significant (P(Wex) < 0.001). On the contemporary panorama in the treatment of psoriasis, we conclude that vitamin B(12) ointment will represent a new concrete therapy option and should be considered in the update of therapeutic algorithm for the treatment of psoriasis
format Online
Article
Text
id pubmed-5806803
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-58068032018-02-28 Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis Del Duca, Ester Farnetani, Francesca De Carvalho, Nathalie Bottoni, Ugo Pellacani, Giovanni Nisticò, Steven P Int J Immunopathol Pharmacol Letters to the Editor Psoriasis is a chronic inflammatory skin disease affecting 2%–3% of the population. The wide range of drugs currently available for its treatment could be associated, in the long term, with organ toxicity and adverse events, thus, clinical monitoring throughout treatment is required. This investigator-initiated trial (IIT) evaluated the efficacy and the safety of a vitamin B(12)-containing ointment in comparison with glycerol-petrolatum-based emollient cream used twice a day to treat mild-to-moderate plaque psoriasis for a period over 12 weeks followed by a wash-out observation period of 4 weeks. This study was conducted as a randomized, controlled, single-blind, intra-patient left- to right-side trial comparing the efficacy and safety of vitamin B(12)-containing ointment (M-treatment) with a glycerol-petrolatum-based emollient cream (C-treatment). The Psoriasis Area Severity Index (PASI) was determined at baseline (T0), at time points T2 (14 days), T4 (4 weeks), T8 (8 weeks), T12 (12 weeks) and 4 weeks after the end of the wash-out period (F1). In total, 24 patients with plaque psoriasis were randomized to receive left- or right-side treatment with B(12) ointment. From time point T2 to time point F1, there was a statistically significant difference in PASI reduction between M-treatment side and C-treatment side. At time point T 12, the difference between the mean reductions from baseline PASI scores by 5.92 ± 2.49 (87, 6%) in the M-treatment side versus 1.08 ± 1.02 (23, 1%) C-treatment side was statistically highly significant (P(Wex) < 0.001). On the contemporary panorama in the treatment of psoriasis, we conclude that vitamin B(12) ointment will represent a new concrete therapy option and should be considered in the update of therapeutic algorithm for the treatment of psoriasis SAGE Publications 2017-10-19 2017-12 /pmc/articles/PMC5806803/ /pubmed/29048238 http://dx.doi.org/10.1177/0394632017736674 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letters to the Editor
Del Duca, Ester
Farnetani, Francesca
De Carvalho, Nathalie
Bottoni, Ugo
Pellacani, Giovanni
Nisticò, Steven P
Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title_full Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title_fullStr Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title_full_unstemmed Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title_short Superiority of a vitamin B(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
title_sort superiority of a vitamin b(12)-containing emollient compared to a standard emollient in the maintenance treatment of mild-to-moderate plaque psoriasis
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806803/
https://www.ncbi.nlm.nih.gov/pubmed/29048238
http://dx.doi.org/10.1177/0394632017736674
work_keys_str_mv AT delducaester superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis
AT farnetanifrancesca superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis
AT decarvalhonathalie superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis
AT bottoniugo superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis
AT pellacanigiovanni superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis
AT nisticostevenp superiorityofavitaminb12containingemollientcomparedtoastandardemollientinthemaintenancetreatmentofmildtomoderateplaquepsoriasis